case_images: PMC10863493_01
case_images: Characterization of Lesions Throughout the Treatment Course. (a and b) hypertrophic and infiltrating nodules of varying sizes on face and hand; (c and d) During the first revisit, the patient reported improved symptoms, including alleviation of itching and a decline in rash; (e and f) during the 2nd revisit after treatment; (g and h) During 4th revisit, rash was almost imperceptible and pruritus was no longer prominent.
case_images: CCID-17-399-g0001.jpg
case_images: PMC10863493_01_CCID-17-399-g0001.jpg
case_images: f0001
case_images: Physical examination revealed hypertrophic and infiltrating nodules of varying sizes with significant scratches and local exudation (Figure 1a and b). During the first revisit (4th weeks after the first dose administration), the patient reported improved symptoms, including alleviation of itching and a decline in rash (Figure 1c and d). The patient underwent subsequent revisits after one month (12th weeks after the first dose) (Figure 1e and f). By the fourth revisit (16th weeks after the first dose), the rash was almost imperceptible and pruritus was no longer prominent (Figure 1g and h).
case_images: Microscopic Examination of Tissue Sections: Histopathological Findings. (a and b) Acanthosis of the epithelium with elonged rete ridges, as well as the lymphocytic infiltration around dermal blood vessels and appendages; (c) Blue arrow; epidermal dyskeratosis and hyperkeratosis, Black arrow; acanthosis with elonged rete ridge, Green arrow; lymphocytic infiltration around dermal blood vessels and appendages.
case_images: CCID-17-399-g0002.jpg
case_images: PMC10863493_01_CCID-17-399-g0002.jpg
case_images: f0002
case_images: A biopsy of the occipital skin confirmed the diagnosis, demonstrating epithelial keratosis, hyperkeratosis, and lymphocytic infiltration around the blood vessels and skin appendages (Figure 2a-c).